Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics is closing in on an important regulatory event. The FDA is considering its potential gene-editing therapy for sickle cell disease.

This Cathie Wood Stock Could Nearly Double, According to Wall Street

CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.

Here's Why You Should Add CRISPR Stock to Your Portfolio

Kala Pharmaceuticals

Ligand Pharmaceuticals

Theseus Pharmaceuticals

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.

4 Biotech Stocks to Consider for Your Portfolio in 2023

Accuray

Illumina

Healthcare costs in America and the world are set to rise in the foreseeable future. All thanks to an aging population, and the expectation that healthcare companies will be able to cure more of our diseases.

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time

Exelixis

Intellia Therapeutics

2023 could be a landmark year for CRISPR Therapeutics. Exelixis has solid fundamentals, plus plenty of upside potential.

3 Beaten-Down Stocks That Could Soar This Year

ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place April 14 – 19, 2023, in Orlando, FL.

CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting

ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities.

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Beam Therapeutics

Editas Medicine

Novartis

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

CRISPR Therapeutics is a clinical-stage biotech company. The company's pipeline includes two promising wholly owned therapies.

Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold

Adyen NV

Caterpillar

Magna International

NVIDIA

Tesla

Investing in Cathie Wood stocks means directing your money toward innovation. And that means investing heavily in tech, a sector that has been pummeled by interest rates held higher by a Federal Reserve battling runaway inflation.

7 Cathie Wood Stocks for Your March Buy List

CRISPR Therapeutics AG (NASDAQ:CRSP ) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 10:30 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Tyler Van Buren Good morning, everyone. Tyler Van Buren here senior biotech analyst at TD Cowen.

CRISPR Therapeutics AG (CRSP) Cowen 43rd Annual Healthcare Conference (Transcript)

The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery.

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

Moderna

Moderna's pipeline programs may drive another huge phase of growth. The potential approval of CRISPR's first product could be a major catalyst for the stock.

Better Growth Stock: Moderna vs. CRISPR Therapeutics

Institutional investors might be on to something.

3 Things About CRISPR Therapeutics That Smart Investors Know

Beam Therapeutics could be a huge winner over the long run with its base-editing therapies.

3 Game-Changing Stocks to Buy in March

Fiverr

Investors are bidding up shares of these companies, and there are good reasons for doing so.

2 Soaring Stocks to Buy and Hold Through 2023 and Beyond

Axcelis Technologies

Amazon

ARK Genomic Revolution Multi-Sector ETF

Celsius Holdings

Alphabet

QUALCOMM

Target

United Rentals

Veeva Systems

These diversified growth stocks could add rocket fuel to your long-term investment portfolio.

10 Best Stocks to Buy in March 2023

CRISPR Therapeutics AG is a gene-editing startup that uses CRISPR/Cas9 technology to develop therapies. The company's most commercially promising therapy is the Exa-cel program, which is close to get to commercial stage.

Beyond Crispr's Exa-Cel Program: A Scalable Pipeline

ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.

CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Doximity

Doing this can strengthen your retirement plan.

Here's How Much You Can Make From Investing Your Tax Return Every Year

CRISPR Therapeutics AG (NASDAQ:CRSP ) Citi's 2023 Virtual Oncology Leadership Summit Conference February 22, 2023 1:00 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Yigal Nochomovitz - Citi Yigal Nochomovitz All right. Great. Welcome, everyone.

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2023 Virtual Oncology Leadership Summit Conference (Transcript)

Crispr's share price spiked a little this week on Q422 earnings. There's a much bigger story unfolding, however - a first-ever approval of a Crispr/Cas9 gene editing cell therapy.

Crispr Therapeutics: I Sense A Long Bull Run As First Approval Approaches

CRISPR Therapeutics AG (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock

Here is how CRISPR Therapeutics AG (CRSP) and Applied Molecular Transport Inc. (AMTI) have performed compared to their sector so far this year.

Has CRISPR Therapeutics (CRSP) Outpaced Other Medical Stocks This Year?

CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.

CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss

News for CRISPR Therapeutics Stock (CRSP)